Picture supply: Getty Photos
Hims & Hers Well being (NYSE:HIMS) must be one of many craziest progress shares I’ve ever held. To provide a flavour, it’s up 97% for the reason that finish of February however nonetheless 50% off the $57 it reached again in September.
Since early 2025, the share value chart has resembled a coronary heart monitor!
Why is it such a bucking bronco?
At a look
As a fast reminder, Hims & Hers is a web based well being platform. It connects sufferers with licensed medical professionals, delivering personalised therapies to their entrance door.
This may very well be for sexual well being, weight reduction, psychological well being, zits, hair loss, low testosterone, or menopause care. Many individuals are too embarrassed to go to a health care provider in particular person for these circumstances, making the anonymity of platforms like Hims & Hers extra interesting.
The corporate has grown exponentially. Final 12 months, income jumped 59% to $2.3bn, up from $149m in 2020. And it has turned worthwhile on this time whereas rising its subscriber base to over 2.5m.
We’re on a mission to reshape the healthcare system with the client on the centre…That is what individuals deserve, whether or not they reside in a rural midwestern neighborhood within the US, a big metropolis within the UK, or someplace in between. We’re shifting quick to construct this new actuality.
Hims & Hers.
Why’s the inventory instantly flying?
The inventory crashed 27% in February when Wegovy maker Novo Nordisk filed a lawsuit towards the agency for patent infringement over an inexpensive compounded tablet model of the best-selling GLP-1 drug.
Since then although, the pair have made up and Hims & Hers now sells branded Ozempic and Wegovy. Buyers clearly welcomed this growth.
Tens of millions of individuals are actually utilizing peptide therapies for issues like anti-ageing, muscle restoration, and cognitive well being (nootropics). GLP-1 itself is a peptide hormone.
For the file, I’ve firsthand expertise right here as a result of I’ve been utilizing a copper peptide for the previous few months. It has considerably improved my pores and skin, making my face look youthful (in accordance with some buddies).
Now, that is nonetheless a regulatory gray space and I’m undoubtedly not malign any suggestions for individuals to make use of peptides. However there was skyrocketing curiosity on this space of longevity and ‘biohacking’ over the previous few months, because the Google Tendencies graph under exhibits.
Supply: Google Tendencies.
Able to manufacture peptides at scale
However how does this profit the enterprise? Nicely, the corporate purchased a specialist peptide manufacturing facility final 12 months. This handles the complicated chemistry wanted for next-generation wellness merchandise.
So with the regulatory panorama seemingly altering, peptides may symbolize one other huge progress driver within the years head.
Would I guess the farm?
The largest danger I see right here is competitors from the likes of Amazon Pharmacy. Additionally, the connection with Novo Nordisk may bitter once more in future, sending the inventory crashing.
Regardless of these potential dangers, I’m nonetheless bullish on the inventory. If the corporate can change into the ‘Amazon of healthcare’, it could doubtless be a monster winner contemplating the comparatively small $6.6bn market cap immediately.
Given the big potential right here, I feel the inventory’s value contemplating. Nevertheless, it’s undoubtedly within the high-risk, high-reward camp, so I wouldn’t guess the farm.
